https://www.selleckchem.com/pr....oducts/sodium-cholat
To determine the median survival time (MST) of dogs with nasal carcinoma treated with toceranib phosphate. The databases of four Spanish referral hospitals were retrospectively searched for dogs with a diagnosis of nasal tumours presented between January 2015 and October 2020. Dogs treated with radiotherapy or other chemotherapies prior toceranib were excluded. Twenty-three dogs with a confirmed nasal carcinoma treated with toceranib phosphate and with a CT scan for initial staging according to Adams Modified Staging System were
Curtir
Comentario
Compartilhar
